Collectively, our in vitro data suggest that restoring BMP signaling with the GREM1-neutralizing antibody promoted differentiation of Lgr5+ intestinal stem cells and attenuated tumoroid growth of Smad4–wild-type, but not Smad4-mutant, CRC. The gene discussed is SMAD4; the disease is colorectal carcinoma.